ALC Stock Chart & Stats
$81.32
-$0.68(-0.81%)
At close: 4:00 PM EST
$81.32
-$0.68(-0.81%)
Day’s Range― - ―
52-Week Range$61.84 - $92.55
Previous Close$87.56
Volume942.02K
Average Volume (3M)1.96M
Market Cap
$33.41B
Enterprise Value$34.97B
Total Cash (Recent Filing)$1.66B
Total Debt (Recent Filing)$5.25B
Price to Earnings (P/E)40.8
Beta0.70
Next Earnings
Aug 10, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend Yield0.41%
Share Statistics
EPS (TTM)1.65
Shares Outstanding499,700,000
10 Day Avg. Volume1,977,140
30 Day Avg. Volume1,961,678
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue3.30
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda15.52
Forecast
1Y Price Target
$87.44Price Target Upside7.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)3.4
Revenue Forecast (FY)$10.89B
Bulls Say, Bears Say
Bulls Say
Balance-sheet Strength And Low LeverageLow debt-to-equity and a sizable equity base provide durable financial flexibility to invest in R&D, absorb temporary shocks, and support capital returns. This conservatism limits solvency risk and underpins multi-year strategic programs like product launches and repurchases without forcing asset sales.
Installed-base & Equipment MomentumStrong equipment placements expand an installed base that drives recurring consumable demand and high customer switching costs. Durable equipment momentum (Unity adoption) increases revenue visibility, supports higher lifetime customer value, and creates a structural annuity from procedure-linked consumables.
Product Innovation And Diversified Growth DriversConsistent product wins across pharmaceuticals, IOLs and ocular health broaden growth levers and reduce single-market reliance. Successful launches with rapid share gains and refill rates indicate sustainable adoption curves, supporting medium-term revenue mix improvement and higher-margin portfolio expansion.
Bears Say
TTM Profit And Free-cash-flow DeteriorationA step-down in trailing net margin and meaningful FCF decline signal weakening earnings quality and cash conversion. Persistently lower cash generation reduces flexibility to fund organic investment and buybacks, raises sensitivity to cost shocks, and lengthens the time to re-lever growth initiatives.
Tariff Pressure And Operational DisruptionsMaterial incremental tariff costs and episodic supply/shipping disruptions directly compress gross margins and increase cost volatility. If tariffs or trade frictions persist, margin recovery from operational improvements may be delayed and planning for long-term margin targets becomes more uncertain.
Exposure To Procedure Cyclicality And China/competitive WeaknessHeavy reliance on cataract procedure volumes and sensitivity to Chinese demand and local competition creates structural revenue risk. Slower procedure growth or intensified IOL competition can limit installed-base growth and recurring consumable sales, making topline and margin recovery more challenging.
Alcon News
ALC FAQ
What was Alcon’s price range in the past 12 months?
Alcon lowest stock price was $61.84 and its highest was $92.55 in the past 12 months.
What is Alcon’s market cap?
Alcon’s market cap is $33.41B.
When is Alcon’s upcoming earnings report date?
Alcon’s upcoming earnings report date is Aug 10, 2026 which is in 30 days.
How were Alcon’s earnings last quarter?
Alcon released its earnings results on May 05, 2026. The company reported $0.819 earnings per share for the quarter, beating the consensus estimate of $0.787 by $0.032.
Is Alcon overvalued?
According to Wall Street analysts Alcon’s price is currently Undervalued.
Does Alcon pay dividends?
Alcon pays a Annually dividend of $0.359 which represents an annual dividend yield of 0.41%. See more information on Alcon dividends here
What is Alcon’s EPS estimate?
Alcon’s EPS estimate is 0.74.
How many shares outstanding does Alcon have?
Alcon has 499,700,000 shares outstanding.
What happened to Alcon’s price movement after its last earnings report?
Alcon reported an EPS of $0.819 in its last earnings report, beating expectations of $0.787. Following the earnings report the stock price went down -11.717%.
Which hedge fund is a major shareholder of Alcon?
Currently, no hedge funds are holding shares in ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$87.44 (7.52% Upside)
$87.44 (7.52% Upside)
Blogger Sentiment
Bullish
ALC Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 251.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.43%
12-Months-Change
Fundamentals
Return on Equity
3.69%
Trailing 12-Months
Asset Growth
1.97%
Trailing 12-Months
Company Description
Alcon
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
ALC Company Deck
ALC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely constructive picture: solid top-line growth across surgical, vision care and ocular health, strong early adoption and share gains from new product launches (Unity, PanOptix Pro, Tryptyr, Total30), a meaningful equipment acceleration and a shareholder-friendly $1.5B repurchase plan. Offsetting this optimism were market headwinds (soft cataract volumes, China weakness), tariff-driven margin pressure, modest operational disruptions (Hydrus supply, Middle East shipping) and near-term margin timing (Q2 SG&A peak). Management maintained full-year guidance (5%–7% sales growth; 70–170 bps core operating margin expansion) and positioned the back half of 2026 for stronger contribution from new products, implying overall confidence in durable growth despite short-term noise.View all ALC earnings summariesALC Stock 12 Month Forecast
Average Price Target
$87.44
▲(7.52% Upside)
Technical Analysis
Ownership Overview
―
Insiders
12.32% Mutual Funds
0.03% Other Institutional Investors
70.65% Public Companies and
Individual Investors